Brofaromine in elderly major depressed patients--a comparative trial versus imipramine.
In an 8-week controlled double-blind clinical trial with a total of 189 elderly patients brofaromine showed comparable efficacy to imipramine (Hamilton Depression Scale, von Zerssen self-rating scale, global evaluation). The numbers of adverse events were the same in both groups, but the spectrum differed distinctly. In the global evaluation of tolerability, there was an advantage for brofaromine. Mean daily doses were 85 mg/day in the brofaromine group and 87 mg/day in the imipramine group. Long-term efficacy and tolerability also proved to be good in the open follow-up of the patients treated with brofaromine.
Möller
H J
HJ
Department of Psychiatry, University of Bonn, Germany.
Volz
H P
HP
D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; C038213:brofaromine; D007099:Imipramine